Singapore, May 10, 2021 -- Currently supported on HECO (Huobi Eco-Chain) and BSC (Binance Smart Chain), CoinWind is a smart yield farming platform that automatically matches pledged tokens to maximize all user revenues.

In the increasingly competitive landscape of DeFi (decentralized finance) yield farming, CoinWind effectively solves issues of both low revenues from single-token mining and high risks from impermanent losses on LP (liquidity pool) mining. Currently the TVL (Total Volume Locked) on the platform is an impressive USD 2.69 Billion.

A Smart Decentralized Finance Management Platform

Positioned as a smart decentralized finance management platform and not simply an aggregator tool, CoinWind focuses on optimizing users’ yields.

The high-yield, safe and reliable platform places tokens deposited by users into the different pools, and mobilizes funds from certain token pools to participate in different liquidity minings, all according to a combination of project selection and mining strategies.

At the same time, this is combined with token price hedging strategies to mitigate impermanent loss in liquidity mining so as to ensure the safety of funds.

The aim is to maximize the rate of returns for users while reducing unpredictable losses.

High Yield Products: Single-Token and LP Farms

Currently launched on HECO and BSC, CoinWind plans to integrate other chains such as ETH and OKT in the future.

According to Musk, Head of CoinWind Community, CoinWind’s competitive edge is in offering low user thresholds and maintaining high yields that work together to attract liquidity providers. In the Chinese DeFi space, the platform is one of the most popular in terms of single-token mining.

Professional project selections include screening audited, popular and relatively stable projects, combined with mining strategies to optimally match up with high-yield pools for highest profit returns as well as hedging strategies to reduce impermanent losses, a frequent concern in yield farming.

CoinWind offers both Single-token (or Single-Asset) mining and LP (liquidity pool) mining opportunities, offering attractive APY (annual percentage yield) with flexible staking.

For single-token mining opportunities, there are currently 16 tokens on HECO and 14 on BSC. Some APY highlights would include MDX token (208.99% on HECO and 305.67% on BSC), USDT (30.08% on HECO and 35.37% on BSC), DOGE (44.85% on HECO), HUSD (33.87% on HECO), UNI (31.44% on HECO), HDMX (140.23% on BSC), BUSD (44.27% on BSC) and WBNB (37.57% on BSC), amongst many others.

For liquidity pool mining opportunities, there are currently 15 pairs on HECO and 15 pairs on BSC. Some APY highlights would include MDX-USDT (215.38% on HECO and 278.73% on BSC), MDX-WHT (207.72% on HECO), MDX-WBNB (376.08% on BSC), MDX-BUSD (402.76% on BSC), MDX-HBTC (191.33% on HECO), MDX-BTCB (341.53% on BSC), WBNB-USDT (74.79% on BSC) and MDX-ETH (232.58% on HECO), amongst many others.

Automatically Reinvests Profits

CoinWind also does not let the income generated in the LP pool lie idle. Every 5 - 10 minutes, it automatically reinvests the profits into high-yield projects and this process is continuously repeated so that incomes are efficiently used to generate optimal profits and it also saves time for the user who would otherwise have to manually process this.

As of this writing, total user revenues have reached USD 85,578,977.14.

Strong Growth Potential MDX Token as Target Value

CoinWind currently uses the MDX token as the target value, a nod to MDEX, the largest platform on HECO and performing well in the competitive BSC environment. The leading DEX (decentralized exchange) implements a unique strategy of dual mining, combining liquidity and transaction mining. This has led to an explosive growth in its platform trading volumes.

Recognizing the stellar performance and strong growth potential of the MDEX platform, CoinWind’s utilization of the MDX token as a core value of exchange on its platform is yet another astute move.

For more info about CoinWind, visit the official website: https://www.coinwind.com

CoinWind official channels:
Twitter: https://twitter.com/coinwind_com
English Telegram: https://t.me/CoinWind
Chinese Telegram: https://t.me/coinwind_cn
Medium: https://mdex.medium.com/

An exciting new study from the team of Lucintel found that CRISPR market is expected to grow at a CAGR of 24%-26%. There are significant money making opportunities available in this market and companies planning to enter this market need to differentiate in order to maximize their return on investment.

Download Brochure of this report by clicking on https://www.lucintel.com/crispr-market.aspx

The CRISPR market is segmented based on segments, such as product, service, application, and end user, and region. In this market, biomedical is largest by application. Players can benefit from the available opportunities like increasing government and private fundings and the presence of major gene therapy and pharma companies in the region.

Cellecta, Thermo Fisher, GeneCopoeia, Applied StemCell, Synthego, OriGene Technologies, Horizon Discovery, Merck, and GenScript are some of the major players profiled in this 150 page report.

Request Sample Pages by clicking on https://www.lucintel.com/crispr-market.aspx

Some of the Key Questions answered in this exclusive report are:

Q.1 What are some of the most promising, high-growth opportunities for the CRISPR market by product (enzymes, kits, gRNA, libraries, and design tools), service (gRNA design and cell line engineering), application (biomedical, agricultural, industrial, and biological research), end user (pharma & biopharma companies, biotechnology companies, academics, and contract research organization), and region (North America, Europe, Asia Pacific, and Rest of the World)?

Q.2 Which segments will grow at a faster pace and why?

Q.3 What are the business risks and threats to the CRISPR market?

Q.4 What are some changing demands of customers in the CRISPR market?

Q.5 What are the new developments in the CRISPR market? Which companies are leading these developments?

Q.6 What strategic initiatives are being implemented by key players for business growth?

Q.7 What are some of the competitive products and processes in this CRISPR area and how big of a threat do they pose for loss of market share via product substitution?

Q.8 What M&A activity has occurred in the last 5 years in this CRISPR market?

This unique report from Lucintel will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link This email address is being protected from spambots. You need JavaScript enabled to view it.

About Lucintel

Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

Brandon Fitzgerald
Lucintel
Dallas, Texas, USA
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel. 972.636.5056
Cell: 303.775.0751

An exciting new study from the team of Lucintel found that life science tool market is expected to grow at a CAGR of 8%-10%. There are significant money making opportunities available in this market and companies planning to enter this market need to differentiate in order to maximize their return on investment.

Download Brochure of this report by clicking on https://www.lucintel.com/life-science-tool-market.aspx

The life science tool market is segmented based on segments, such as product, technology, end use, and region. In this market, separation technologies are the largest segment by product, whereas healthcare is largest by end use. Players can benefit from the available opportunities like increasing research and development activities and rising genomic procedures for academic and clinical use.

Agilent Technologies, B&D, Roche, Bio-Rad Laboratories, Bruker, Danaher, GE Healthcare, Hitachi, Illumina, and Merck are some of the major players profiled in this 150 page report.

Request Sample Pages by clicking on https://www.lucintel.com/life-science-tool-market.aspx

Some of the Key Questions answered in this exclusive report are:

Q.1 What are some of the most promising, high-growth opportunities for the Life science tool market by product (sanger sequencing, NGS, nucleic acid preparation, PCR & qPCR, nucleic acid microarray, flow cytometry, separation technologies, mass spectrometry, electron microscopy, NMR, and others), technology (cell biology, proteomics, genomics, other analytical & sample preparation technology, and lab supplies & technologies), end use (government & academic, biopharmaceutical company, health care, industry, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?

Q.2 Which segments will grow at a faster pace and why?

Q.3 What are the business risks and threats to the life science tool market?

Q.4 What are some changing demands of customers in the life science tool market?

Q.5 What are the new developments in the life science tool market? Which companies are leading these developments?

Q.6 What strategic initiatives are being implemented by key players for business growth?

Q.7 What are some of the competitive products and processes in this life science tool area and how big of a threat do they pose for loss of market share via product substitution?

Q.8 What M&A activity has occurred in the last 5 years in this life science tool market?

This unique report from Lucintel will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link This email address is being protected from spambots. You need JavaScript enabled to view it.

About Lucintel

Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

Brandon Fitzgerald
Lucintel
Dallas, Texas, USA
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel. 972.636.5056
Cell: 303.775.0751

An exciting new study from the team of Lucintel found that RNAi technology market is expected to grow at a CAGR of 7%-9%. There are significant money making opportunities available in this market and companies planning to enter this market need to differentiate in order to maximize their return on investment.

Download Brochure of this report by clicking on https://www.lucintel.com/rnai-technology-market.aspx

The RNAi technology market is segmented based on therapeutic area, application,  and region. In this market, oncology is the largest segment by therapeutic area. Players can benefit from the available opportunities like increasing investment by biotechnology companies for RNAi therapeutic development.

Advancement in technologies such as small interfering RNA (siRNA) tolerant to nucleases and non-viral vectors, such as cationic liposomes and nanoparticles are emerging trends having impact on dynamics of the industry.

Affymetrix, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare, Illumina, Qiagen, Roche, Sigma Aldrich, Fluidigm, and Thermofisher Scientific are some of the major players profiled in this 150 page report.

Request Sample Pages by clicking on

https://www.lucintel.com/rnai-technology-market.aspx

Some of the Key Questions answered in this exclusive report are:

Q.1 What are some of the most promising, high-growth opportunities for the RNAi technology market by therapeutic area (oncology, ocular disorders, respiratory disorders, liver diseases, and neuronal disorders), application (drug discovery & development, therapeutics, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?

Q.2 Which segments will grow at a faster pace and why?

Q.3 What are the business risks and threats to the RNAi technology market?

Q.4 What are some changing demands of customers in the RNAi technology market?

Q.5 What are the new developments in the RNAi technology market? Which companies are leading these developments?

Q.6 What strategic initiatives are being implemented by key players for business growth?

Q.7 What are some of the competitive products and processes in this RNAi technology area and how big of a threat do they pose for loss of market share via product substitution?

Q.8 What M&A activity has occurred in the last 5 years in this RNAi technology market?

This unique report from Lucintel will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link This email address is being protected from spambots. You need JavaScript enabled to view it.

About Lucintel

Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

Brandon Fitzgerald
Lucintel
Dallas, Texas, USA
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel. 972.636.5056
Cell: 303.775.0751